4d Molecular Therapeutics Stock Investor Sentiment

FDMT Stock  USD 7.50  0.12  1.57%   
Slightly above 66% of 4D Molecular's investor base is looking to short. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that many traders are alarmed. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
  

4D Molecular Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 4D Molecular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at marketwatch.com         
4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment Trial
marketwatch News
over six months ago at investing.com         
Why 4D Molecular Therapeutics stock is up 100 percent today
Investing News at Macroaxis
over six months ago at marketwatch.com         
4D Molecular Therapeutics Shares Rise 33 percent After Positive Trial Data
marketwatch News
over six months ago at globenewswire.com         
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-...
Macroaxis News: globenewswire.com
over six months ago at benzinga.com         
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravit...
benzinga news
over six months ago at news.google.com         
Should You Add 4D Molecular Therapeutics Inc Stock to Your Portfolio Friday - InvestorsObserver
Google News at Macroaxis
over six months ago at news.google.com         
Sale by Kirn David of 5696 shares of 4D Molecular
Google News at Macroaxis
over six months ago at seekingalpha.com         
4D Molecular gets FDA rare pediatric disease status for CF drug
seekingalpha News
over six months ago at zacks.com         
All You Need to Know About 4D Molecular Therapeutics, Inc. Rating Upgrade to Strong Buy
zacks News
over six months ago at thelincolnianonline.com         
Analysts Offer Predictions for 4D Molecular Therapeutics, Inc.s Q1 2024 Earnings
news
over six months ago at gurufocus.com         
4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares
Gurufocus Stories at Macroaxis
over six months ago at www.macroaxis.com         
Sale by Kirn David of 28632 shares of 4D Molecular
Macroaxis News
over six months ago at www.macroaxis.com         
Sale by Viking Global Investors Lp of 540000 shares of 4D Molecular
Macroaxis News
over six months ago at thelincolnianonline.com         
4D Molecular Therapeutics, Inc. Short Interest Up 9.2 percent in December
news
over six months ago at thelincolnianonline.com         
4D Molecular Therapeutics vs. Disc Medicine Head-To-Head Comparison
news
Far too much social signal, news, headlines, and media speculation about 4D Molecular that are available to investors today. That information is available publicly through FDMT media outlets and privately through word of mouth or via FDMT internal channels. However, regardless of the origin, that massive amount of FDMT data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 4D Molecular news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 4D Molecular relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 4D Molecular's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 4D Molecular alpha.

4D Molecular Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Kirn David of 11653 shares of 4D Molecular at 14.42 subject to Rule 16b-3
09/04/2024
2
4d Molecular Therapeutics executive sells 8.2k in stock
09/18/2024
3
Shareholders Are Encouraged To Join The Schall Law Firms Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions
10/03/2024
4
The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud
10/16/2024
5
Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
10/25/2024
6
Vanguard Group Incs Strategic Acquisition of Shares in 4D Molecular Therapeutics Inc
11/05/2024
7
Disposition of 240000 shares by Bvf Partners L Pil of 4D Molecular subject to Rule 16b-3
11/08/2024
8
4D Molecular Therapeutics Inc Reports Q3 2024 EPS of and Revenue of 3,000
11/13/2024
9
Deep Track Capital, LP Increases Stake in 4D Molecular Therapeutics Inc
11/14/2024
10
4D Molecular initiated by Morgan Stanley at underweight
11/21/2024

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.